TL;DR: A 2026 Journal of Global Health analysis of Global Burden of Disease 2021 data estimated that 162.86 million people had substance use disorders in 2021, with age-standardized rates down since 1990 but major inequality across sex, age, region, and development level. Key Findings 162.86 million cases: Global Burden of Disease 2021 estimates put worldwide …
TL;DR: A 2026 systematic review and meta-analysis in International Journal of Obesity found that glucagon-like peptide-1 receptor agonists, metabolic drugs that extend a satiety and glucose-control hormone pathway, reduced body weight mainly through fat loss while lean-mass reductions were generally modest. Key Findings 36 studies reviewed: Researchers included 36 studies in the qualitative review and …
TL;DR: A 2026 review in Drug Design, Development and Therapy argued that glucagon-like peptide-1 (GLP-1) receptor agonists, drugs that mimic a metabolic hormone involved in glucose control, have credible brain-protection mechanisms, but clinical evidence for neurological disorders remains mixed. Key Findings 15-page review: Li et al. summarized GLP-1 receptor agonist mechanisms and evidence across neurodegenerative, …
TL;DR: A 2025 study in Journal of the American Chemical Society used photochemistry to turn amino-acid-linked tryptamines into azocinoindoles that activated serotonin 5-HT2A signaling while suppressing the mouse head-twitch response. Key Findings C4 indole route: The method used light-induced cyclization to functionalize the indole ring at the C4 position. Amino-acid inputs: Amino acids were coupled …
TL;DR: A 2026 mouse study in The Journal of Neuroscience found that the HIV-1 protein gp120 amplified pain signaling through α2δ-1-bound NMDA receptors in spinal excitatory neurons, and blocking that receptor coupling reversed pain-like hypersensitivity. Key Findings More than 60% chronic pain: The source context notes that sensory neuropathy and chronic pain affect more than …
TL;DR: A 2025 study in Neurology used a Kaiser Permanente target-trial emulation and found that starting a statin was not linked to higher or lower Alzheimer disease or related dementia incidence after the first year. The first-year diagnosis increase likely reflected more medical contact after a new prescription. Key Findings No difference after year one: …
TL;DR: A 2026 review in CNS Drugs argues that seletracetam, an unapproved SV2A-targeting antiseizure drug, may deserve renewed development as a low-volume intranasal non-benzodiazepine rescue treatment for acute repetitive seizures. Key Findings SV2A racetam: Seletracetam is a second-generation racetam related to levetiracetam and brivaracetam. Phase IIa history: Oral seletracetam reached early clinical trials but was …
TL;DR: A 2026 review in Purinergic Signalling argues that ATP-gated P2X receptors, especially P2X7 and P2X4, may connect stress-related neuroinflammation with depression and bipolar-disorder biology. Key Findings P2X7 focus: The review describes P2X7 receptor signaling as a major link between stress, microglial activation, NLRP3 inflammasome signaling, cytokine release, and lower neuroplasticity. P2X4 context: P2X4 receptors …
TL;DR: A 2026 systematic review and meta-analysis in BMC Psychiatry reported that olanzapine produced a numerically higher body mass index gain in anorexia nervosa trials, but the pooled randomized evidence remained small, heterogeneous, and not statistically significant. Key Findings 7 RCTs included: The review found 7 randomized controlled trials with 152 people treated for anorexia …
TL;DR: A 2026 open-label feasibility trial in IBRO Neuroscience Reports tested an AI-guided variable levodopa schedule in 5 people with Parkinson’s disease and found 4 patients improved on UPDRS, but the study was far too small and uncontrolled to prove efficacy. Key Findings Feasibility sample: The single-center trial enrolled 5 people with Parkinson’s disease after …
